UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.1023-1028

2014

Volltextzugriff (PDF)

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

Bioorganic & medicinal chemistry, 2012-02, Vol.20 (3), p.1271-1280

2012

Volltextzugriff (PDF)

Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer

Molecular cancer therapeutics, 2018-12, Vol.17 (12), p.2519-2529

2018

Volltextzugriff (PDF)

Prediction of Drug-Drug Interactions based on Time-Dependent Inhibition from High Throughput Screening of Cytochrome P450 3A4 Inhibition

DRUG METABOLISM AND PHARMACOKINETICS, 2009-01, Vol.24 (6), p.500-510

2009

Volltextzugriff (PDF)

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Chemical and Pharmaceutical Bulletin, 2008/11/01, Vol.56(11), pp.1555-1561

2008

Volltextzugriff (PDF)

Metabolites of alectinib in human: their identification and pharmacological activity

Heliyon, 2017-07, Vol.3 (7), p.e00354-e00354, Article e00354

2017

Volltextzugriff (PDF)

Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties

ACS medicinal chemistry letters, 2013-11, Vol.4 (11), p.1059-1063

2013

Volltextzugriff (PDF)

In vitro metabolism of alectinib, a novel highly potent alk inhibitor: Contribution of CYP3A enzymes in microsomes and hepatocytes

Drug metabolism and pharmacokinetics, 2017-01, Vol.32 (1), p.S80-S81

2017

Volltextzugriff (PDF)

Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning

ACS medicinal chemistry letters, 2014-04, Vol.5 (4), p.309-314

2014

Volltextzugriff (PDF)

Assessment of Abuses of Children with Disabilities in Japanese Nursery Schools by Municipality

Journal of Intellectual Disability - Diagnosis and Treatment, 2023-02, Vol.11 (1), p.1-9

2023

Volltextzugriff (PDF)

Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor

Journal of medicinal chemistry, 2022-09, Vol.65 (18), p.12427-12444

2022

Volltextzugriff (PDF)

An Assessment of Abuse of Children with Disabilities at Japanese Nursery Schools: Reports by Commissioned Pediatricians

Journal of Intellectual Disability - Diagnosis and Treatment, 2022-02, Vol.10 (1), p.31-36

2022

Volltextzugriff (PDF)

In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Xenobiotica, 2018-06, Vol.48 (6), p.546-554

2018

Volltextzugriff (PDF)

Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib

Xenobiotica, 2017-12, Vol.47 (12), p.1042-1051

2017

Volltextzugriff (PDF)

Estimation of Abuse by Teachers in Special Needs Schools in Japan

Journal of Intellectual Disability - Diagnosis and Treatment, 2021-02, Vol.9 (1), p.113-119

2021

Volltextzugriff (PDF)

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

Chemical and Pharmaceutical Bulletin, 2009/10/01, Vol.57(10), pp.1178-1178

2009

Volltextzugriff (PDF)

9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors

Journal of medicinal chemistry, 2011-09, Vol.54 (18), p.6286-6294

2011

Volltextzugriff (PDF)

Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.754-754

2014

Volltextzugriff (PDF)

The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors

Bioorganic & medicinal chemistry letters, 2013-12, Vol.23 (23), p.6223-6227

2013

Volltextzugriff (PDF)

Abstract 2789: Discovery of a novel specific MEK and Raf inhibitor, CH5126766 (RO5126766), hit to lead study of a unique scaffold for kinase inhibitor to a clinical compound

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2789-2789

2011

Volltextzugriff (PDF)

9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5 H -benzo[ b ]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors

Journal of medicinal chemistry, 2011-09, Vol.54 (18), p.6286-6294

2011

Volltextzugriff (PDF)

Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3593-3593

2011

Volltextzugriff (PDF)

ALK(anaplastic lymphoma kinase)選択的阻害剤アレクチニブの創製

ファルマシア, 2017, Vol.53(6), pp.570-574

2017

Volltextzugriff (PDF)

EML4-ALK融合遺伝子

ファルマシア, 2017, Vol.53(6), pp.575_4-575_4

2017

Volltextzugriff (PDF)

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11)

Chemical & pharmaceutical bulletin, 2009-10, Vol.57 (10)

2009

Volltextzugriff (PDF)

1 – 25 von 250

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(206)

Publikationsform

Sprache

Englisch
(220)
Japanisch
(41)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer

Prediction of Drug-Drug Interactions based on Time-Dependent Inhibition from High Throughput Screening of Cytochrome P450 3A4 Inhibition

Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives

Metabolites of alectinib in human: their identification and pharmacological activity

Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties

In vitro metabolism of alectinib, a novel highly potent alk inhibitor: Contribution of CYP3A enzymes in microsomes and hepatocytes

Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning

Assessment of Abuses of Children with Disabilities in Japanese Nursery Schools by Municipality

Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor

An Assessment of Abuse of Children with Disabilities at Japanese Nursery Schools: Reports by Commissioned Pediatricians

In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib

Estimation of Abuse by Teachers in Special Needs Schools in Japan

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure–Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11): 1555-1561 (2008)]

9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors

Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases

The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors

Abstract 2789: Discovery of a novel specific MEK and Raf inhibitor, CH5126766 (RO5126766), hit to lead study of a unique scaffold for kinase inhibitor to a clinical compound

9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5 H -benzo[ b ]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors

Abstract 3593: Generation of a potent and selective inhibitor of ALK, CH5424802, showing superior oral bioavailability, PK profile and in vivo efficacy

ALK(anaplastic lymphoma kinase)選択的阻害剤アレクチニブの創製

EML4-ALK融合遺伝子

Errata: Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives [Chem. Pharm. Bull. 56(11)

Suchergebnisse filtern